
| Pair Name | Lycorine hydrochloride, Anti-CTLA-4 | |||
| Partner Name | Lycorine hydrochloride | |||
| Disease Info | [ICD-11: 2C90.0] | Renal cell carcinoma | Investigative | |
| Biological Phenomena | Inhibition-->Immune checkpoint | |||
| Gene Regulation | Down-regulation | Expression | CCND1 | hsa595 |
| Down-regulation | Expression | CCND3 | hsa896 | |
| Down-regulation | Expression | CDK2 | hsa1017 | |
| In Vitro Model | Caki-1 | Clear cell renal cell carcinoma | Homo sapiens (Human) | CVCL_0234 |
| ACHN | Papillary renal cell carcinoma | Homo sapiens (Human) | CVCL_1067 | |
| KPK1 | Renal cell carcinoma | Homo sapiens (Human) | CVCL_F947 | |
| RenCa | Mouse kidney carcinoma | Mus musculus (Mouse) | CVCL_2174 | |
| In Vivo Model | Renca-Luc cells were inoculated into the sub-renal capsule kidney (3×10⁵ cells in 50 μl PBS) and tail vein (2×10⁵ cells in 30 μl PBS) of C57BL/6 mice to produce an orthotopic tumor and metastatic lung tumors. | |||
| Result | Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma | |||